SILO PHARMA INC (SILO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.40-2.04%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Silo Pharma is advancing its Nasdaq listing compliance, which supports its market presence. The company has a stock repurchase program authorized for up to $1 million, showing capital return intent. Its focus on novel psychedelic therapies targets unmet mental health needs. The recent asset purchase agreement adds potential growth through new software.
Silo Pharma is loss-making with negative free cash flow yield of -5%. The stock has fallen 43% from its high, reflecting market doubts. Capital allocation has been volatile with multiple unregistered equity sales. The company faces high risk and uncertain revenue growth with no analyst estimates available.
The market prices in significant risk and uncertainty given the 43% drawdown and lack of forward estimates. Our fair value is $1.11, reflecting optionality but also the current loss-making status. The market likely expects continued volatility and slow progress.
Breaks if: Repurchase program not executed or canceled
Breaks if: Loss of Nasdaq listing compliance
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment with a focus on the healthcare sector. The current thesis state indicates a watchful approach due to recent volatility and mixed performance.
The market seems to price in a high level of fragility, as SILO is considered expensive compared to its peers. There is an expectations gap, suggesting that the current valuation may not be justified given the company's loss-making status.
Fundamentals are likely to remain under pressure due to high near-term risk, including a significant probability of an earnings miss. Recent changes show a slight improvement in company quality, but overall performance remains neutral.
The long-term thesis hinges on the performance of sector bellwethers and the company's ability to execute on its management priorities. Key triggers include the success of capital raises and compliance with Nasdaq listing requirements.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company received a Canadian patent allowance for its SPC-15 drug. This patent supports the advancement of clinical and AI platform development. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Pipeline development stalls or regulatory setbacks occur
In the next 1 to 3 years, SILO's performance will depend heavily on external market conditions and internal execution. Not investment advice.